BRIDGEWATER, N.J.--(BUSINESS WIRE)--Senesco Technologies, Inc. (“Senesco” or the “Company”) (OTCQB:SNTI), completed its acquisition of Fabrus, Inc. (“Fabrus”), a biotechnology company focused on expanding the clinical impact of antibodies by addressing drug targets resistant to traditional antibody discovery methods.
Help employers find you! Check out all the jobs and post your resume.
